nach oben

Erschienen in:

05.03.2020 | Original Research Article

Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime

verfasst von: Jiajun Liu, Michael Neely, Jeffrey Lipman, Fekade Sime, Jason A. Roberts, Patrick J. Kiel, Sean N. Avedissian, Nathaniel J. Rhodes, Marc H. Scheetz

Erschienen in: Clinical Pharmacokinetics | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Understanding pharmacokinetic disposition of cefepime, a β-lactam antibiotic, is crucial for developing regimens to achieve optimal exposure and improved clinical outcomes. This study sought to develop and evaluate a unified population pharmacokinetic model in both pediatric and adult patients receiving cefepime treatment.

Methods

Multiple physiologically relevant models were fit to pediatric and adult subject data. To evaluate the final model performance, a withheld group of 12 pediatric patients and two separate adult populations were assessed.

Results

Seventy subjects with a total of 604 cefepime concentrations were included in this study. All adults (n = 34) on average weighed 82.7 kg and displayed a mean creatinine clearance of 106.7 mL/min. All pediatric subjects (n = 36) had mean weight and creatinine clearance of 16.0 kg and 195.6 mL/min, respectively. A covariate-adjusted two-compartment model described the observed concentrations well (population model R², 87.0%; Bayesian model R², 96.5%). In the evaluation subsets, the model performed similarly well (population R², 84.0%; Bayesian R², 90.2%).

Conclusion

The identified model serves well for population dosing and as a Bayesian prior for precision dosing.

Nur mit Berechtigung zugänglich

Bhat SV, Peleg AY, Lodise TP Jr, Shutt KA, Capitano B, Potoski BA, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob Agents Chemother. 2007;51(12):4390–5.CrossRefPubMedPubMedCentral

Rhodes NJ, Liu J, McLaughlin MM, Qi C, Scheetz MH. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC. Diagn Microbiol Infect Dis. 2015;82(2):165–71.CrossRefPubMed

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 26th ed. CLSI supplement M100. Waye (PA): Clinical and Laboratory Standards Institute; 2016.

Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10 (quiz 1–2).

Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, et al. Defining clinical exposures of cefepime for Gram-negative bloodstream infections that are associated with improved survival. Antimicrob Agents Chemother. 2015;60(3):1401–10.CrossRefPubMed

Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(3):1111–6.CrossRefPubMed

Yamashita Y, Kamiyama H, Yamamoto A, Kanoh H, Yuhki Y, Ueda A, et al. Relationship between PK/PD of cefepime and clinical outcome in febrile neutropenic patients with normal renal function. Yakugaku Zasshi. 2016;136(12):1641–9.CrossRefPubMed

Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22(1–2):89–96.

Hospira, Inc. Maxipine (cefepime hydrochloride) [package insert]. US FDA. Revised June 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf. Accessed 16 Aug 2019.

10.

Daigle D, Hamrick J, Chatwin C, Kurepina N, Kreiswirth BN, Shields RK, et al. 1370. Cefepime/VNRX-5133 broad-spectrum activity is maintained against emerging KPC- and PDC-variants in multidrug-resistant K. pneumoniae and P. aeruginosa. Open Forum Infect Dis. 2018;5(Suppl. 1):S419–20.

11.

Reed MD, Yamashita TS, Knupp CK, Veazey JM Jr, Blumer JL. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. Antimicrob Agents Chemother. 1997;41(8):1783–7.CrossRefPubMedPubMedCentral

12.

Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–83.CrossRefPubMed

13.

Sime FB, Roberts MS, Tiong IS, Gardner JH, Lehman S, Peake SL, et al. Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother. 2015;59(9):5463–9.CrossRefPubMedPubMedCentral

14.

Whited L, Grove M, Rose D, Rhodes NJ, Scheetz MH, O’Donnell JN, et al. Pharmacokinetics of cefepime in patients with cancer and febrile neutropenia in the setting of hematologic malignancies or hematopoeitic cell transplantation. Pharmacotherapy. 2016;36(9):1003–10.CrossRefPubMed

15.

Food and Drug Administration. Guidance Document: Population Pharmacokinetics Guidance for Industry. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics. Published July, 2019. Accessed 15 Aug 2019.

16.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed

17.

Leary R, Jelliffe R, Schumitzky A, Van Guilder M. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) population models. In: Proceedings 14th IEEE symposium on computer-based medical systems. CBMS 2001, Bethesda, MD, USA, 2001, pp. 389–394.

18.

Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34(4):467–76.CrossRefPubMedPubMedCentral

19.

R Core Team. R: a language and environment for statistical computing. 2019. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org/. Accessed 20 Feb 2020.

20.

Okamoto MP, Nakahiro RK, Chin A, Bedikian A. Cefepime clinical pharmacokinetics. Clin Pharmacokinet. 1993;25(2):88–102.CrossRefPubMed

21.

Kovarik JM, ter Maaten JC, Rademaker CM, Deenstra M, Hoepelman IM, Hart HC, et al. Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother. 1990;34(10):1885–8.CrossRefPubMedPubMedCentral

22.

Georges B, Conil JM, Seguin T, Dieye E, Cougot P, Decun JF, et al. Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. Int J Clin Pharmacol Ther. 2008;46(4):157–64.CrossRefPubMed

23.

Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 2009;53(7):2974–81.CrossRefPubMedPubMedCentral

24.

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–96.CrossRefPubMed

25.

Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis. 2007;44(1):79–86.CrossRefPubMed

26.

Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015;70(12):3178–83.PubMed

27.

Office of the Press Secretary. The White House. FACT SHEET: President Obama’s Precision Medicine Initiative. 2015. https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative. Published January 30, 2015. Accessed 15 Aug 2019.

28.

Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood). 2018;37(5):694–701.CrossRefPubMedPubMedCentral

29.

Gameiro GR, Sinkunas V, Liguori GR, Auler-Junior JOC. Precision medicine: changing the way we think about healthcare. Clinics (Sao Paulo). 2018;3(73):e723.

30.

Food and Drug Administration UoNC. Precision dosing: defining the need and approaches to deliver individualized drug dosing in the real-world setting.; August 12, 2019, 2019; FDA White Oak Campus Federal Research Center 10903 New Hampshire Ave. Silver Spring, MD 20993.

31.

Food and Drug Administration. Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment. 2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-cefepime-and-risk-seizure-patients-not-receiving-dosage-adjustments. Published January 19, 2016. Accessed 15 Aug 2019.

32.

Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS. Characterizing cefepime neurotoxicity: a systematic review. Open Forum Infect Dis. 2017;4(4):ofx170.

33.

Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54(10):4360–7.CrossRefPubMedPubMedCentral

34.

Huwyler T, Lenggenhager L, Abbas M, Ing Lorenzini K, Hughes S, Huttner B, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect. 2017;23(7):454–9.CrossRefPubMed

35.

Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. J Infect Chemother. 2016;22(2):78–83.CrossRefPubMed

36.

Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003–9.CrossRefPubMedPubMedCentral

37.

Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009;53(4):1476–81.CrossRefPubMedPubMedCentral

38.

Shoji K, Bradley JS, Reed MD, van den Anker JN, Domonoske C, Capparelli EV (2016) Population pharmacokinetic assessment and pharmacodynamic implications of pediatric cefepime dosing for susceptible-dose-dependent organisms. Antimicrob Agents Chemother. 60(4):2150–2156CrossRefPubMedPubMedCentral

39.

Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003;47(6):1853–61.CrossRefPubMedPubMedCentral

Titel: Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime
verfasst von: Jiajun Liu
Michael Neely
Jeffrey Lipman
Fekade Sime
Jason A. Roberts
Patrick J. Kiel
Sean N. Avedissian
Nathaniel J. Rhodes
Marc H. Scheetz
Publikationsdatum: 05.03.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 8/2020
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-020-00873-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime

Abstract

Background and Objective

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background and Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease

Drug–Drug Interactions with Direct Oral Anticoagulants

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV

Evaluation of Therapeutic Equivalence for the Follow-On Version of Intravenously Administered Non-Biological Complex Drugs

Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children